CentryMed is a biopharmaceutical company located in Frederick, Maryland, neighboring the National Cancer Institute (NCI) and numerous pioneering biotechnology companies and supporting entities. Since its founding in 2018, CentryMed has been dedicated to discovering and developing safer and more effective biotherapeutics for the treatment of various diseases.
About Us
01 / Mission
CentryMed’s mission is to discover and develop antibody-based therapeutics that meet the requirements of patients who have no or limited therapeutic options.
02 / Vision
One of our major focuses is designing novel classes of bispecific and trispecific antibodies that are capable of more selectively targeting cancer cells and overcoming the immunosuppressive microenvironment of solid tumors. Another major focus is using the “magic bullets” to target molecules that are present specifically on cancer stem cells, aiming at downsizing the cell reservoirs and functionally curing the disease.
03 / Value
We strongly believe that together, we can make a difference. We are dedicated to improving life quality of patients by using cutting-edge technologies. We are open-minded and work hard while maintaining a healthy work-life balance.
Tailoring Antibody Affinities for Larger Therapeutic Windows
Antigen-binding activities are not only essential for biological functions but also modulate toxicity of antibodies. Optimal antibody affinities help to minimize toxicity while preserving their biological efficacy leading to larger therapeutic windows. HBiAb (H-shaped bispecific antibody) and iBiAb (i-shaped bispecific antibody) are two of CentryMed's proprietary bispecific antibody formats which are designed to tailor antigen-binding activity by exploiting nonstructural polypeptide linkers of varying lengths and compositions which create different levels of steric occlusion. This approach eliminates the need of mutagenesis which might cause immunogenicity of antibodies in humans.
We are currently focusing most of our efforts and resources on the preclinical development of five products against cancer but more candidates are being added into the pipeline to treat other indications including autoimmune diseases.
PRODUCT INFORMATION
Name
Type
Target
Indication
DNV3 mAb LAG-3 Solid tumor
SMET12 HBiAb Undisclosed Solid tumor
CMD001 HBiAb Undisclosed Colon cancer
CMD002 HBiAb Undisclosed AML, ALL
CMD003 Biparatopic Undisclosed Solid tumor
STATUS
Discovery
Preclinical
Phase 1
PRECLINICAL
PHASE 1
Monoclonal antibody
Bispecific T cell engager
Biparatopic antibody
Contact Us
For general inquiries, please contact: inquiry@centrymedus.com
For collaboration and investment opportunities, please contact: partnership@centrymedus.com
For media requests, please contact: media@centrymedus.com
5107 Pegasus Court, Suite L
Frederick, MD 21704
Contact Us
For general inquiries, please contact: inquiry@centrymedus.com
For collaboration and investment opportunities, please contact: partnership@centrymedus.com
For media requests, please contact: media@centrymedus.com
Address:
5107 Pegasus Court, Suite L
Frederick, MD 21704
Website:
Partnership
The company’s success requires collaborative efforts. We are establishing partnerships with pharmaceutical peers and research institutes globally. We are also seeking investments to move our innovative products from the bench to bedside.
If you are interested, please contact us to discuss opportunities for scientific collaboration and partnerships.
MabPlex
